Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Kynapid cardioversion

Kynapid cardioversion

Kynapid cardioversion
Patients in the Kynapid Phase III trials received an initial infusion of 3 mg/kg over 10 minutes. If conversion to

Read the full 243 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE